Rigel Pharmaceuticals
Clinical trials sponsored by Rigel Pharmaceuticals, explained in plain language.
Develops treatments for hematologic disorders and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study checks if cancer drug olutasidenib changes how other medicines work Results expected Apr 2027 (estimated)
- Cancer drug pralsetinib may change how the body processes other medications Results expected Jul 2027 (estimated)
-
New hope for young brain cancer patients: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…
Phase 2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug R289 offers hope for blood disorder patients who failed other therapies
Disease control Recruiting nowThis study tests an experimental drug called R289 in about 86 adults with a type of blood cancer called lower-risk myelodysplastic syndromes (MDS). Participants must have tried other standard treatments without success. The main goal is to check the drug's safety and side effects…
Phase 1/2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New study checks if cancer drug olutasidenib changes how other medicines work
Knowledge-focused Recruiting nowThis study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…
Phase 4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Cancer drug pralsetinib may change how the body processes other medications
Knowledge-focused Recruiting nowThis study looks at how the cancer drug pralsetinib (Gavreto) affects the way the body breaks down other drugs and hormones. Researchers will give a cocktail of common medications and a hormone-based contraceptive to people with advanced solid tumors, then measure how pralsetinib…
Phase 4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC